Cost-effectiveness of icosapent ethyl for primary and secondary cardiovascular prevention in the UK

Back

ESC Professional Premium Access

Cost-effectiveness of icosapent ethyl for primary and secondary cardiovascular prevention in the UK

Session: Costs and cost-effectiveness

Topic: Health Economics

Speaker: Doctor D. Michaeli (Mannheim, DE) Mr T. Michaeli (Mannheim, DE)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speakers

Doctor Doctor Daniel Tobias Michaeli

University Medical Centre of Mannheim, Mannheim (Germany)

1 presentation

0 follower

Mr Thomas Michaeli

Mannheim (Germany)

1 presentation

0 follower

6 more presentations in this session

Cost-effectiveness of clopidogrel versus ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome

Speaker: Mr W. van den Broek (Nieuwegein, NL)

Access

Abstract

Slides

Dutch Nationwide Implementation Program for familial hypercholesterolemia case finding in children: a cost-effectiveness and return on investment analysis

Speaker: Associate Professor Z. Ademi (Melbourne, AU)

Access

Abstract

Slides

Cost-effectiveness of statin therapy in categories of patients in the UK

Speaker: Associate Professor B. Mihaylova (Oxford, GB)

Access

Abstract

Slides

Healthcare utilization and costs associated with a diagnosis of incident atrial fibrillation

Speaker: Ms T. Beaulieu (Manhattan, US)

Access

Abstract

Slides

Counting the cost of progressive aortic valve stenosis: an international observational clinical cohort study

Speaker: Professor S. Stewart (Sydney, AU)

Access

Abstract

Slides

Access the full session

Costs and cost-effectiveness

Speakers: Doctor D. Michaeli, Mr T. Michaeli, Mr W. van den Broek, Associate Professor Z. Ademi, Associate Professor B. Mihaylova...

Access

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources